International boom: Yiling Pharmaceutical sees overseas revenue soar amid COVID-19 interest in Lianhua Qingwen botanical Yiling Pharmaceutical, the company behind TCM/dietary supplement product Lianhua Qingwen, said revenue from its overseas market was up 918.37 per cent in FY2020, after the product was officially recognised by the China authorities as a COVID-19 standard therapy for mild symptoms such as fever and cough.
Yiling Pharmaceutical’s growth in the overseas markets last year started from a small base of RMB$29m (US$4.56m) in FY2019.
This grew to RMB$304m (US$46m) last year. Revenue from the overseas markets now occupies 3.46 per cent of the company’s total revenue.